Results 61 to 70 of about 6,560 (205)

Molnupiravir. Marshallese

, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 MARSHALLESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and

core  

The Fitness of Molnupiravir-Signed SARS-CoV-2 Variants: Imputation Analysis Based on Prescription Counts and Global Initiative on Sharing All Influenza Data Analyses by Country

Intervirology
Introduction: Molnupiravir is one of the oral direct-acting antivirals against SARS-CoV-2, largely deployed during the COVID-19 pandemic since the 2022 Omicron wave. While efficacy has been questioned in post-marketing clinical trials (leading
Daniele Focosi, Dave McNally, Fabrizio Maggi   +2 more
doaj   +1 more source

Coronavirus M Protein Hijacks Toll‐Interacting Protein (TOLLIP) to Suppress NF‐κB Signaling and Promote Immune Evasion

MedComm, Volume 7, Issue 7, July 2026.
Under physiological conditions, pathogenic stimuli activate TLR/IL1‐R signaling, triggering TOLLIP dissociation from IRAK1 and subsequent IRAK1 phosphorylation, TRAF6 ubiquitination, and NF‐κB activation. During SARS‐CoV‐2 infection, viral M protein binds TOLLIP and stabilizes the TOLLIP–IRAK1 complex, thereby suppressing NF‐κB signaling, impairing ...
Yabin Zhang, Lu Kang, Yu Zhong, Songjun Shao, Senren Xue, Changliang Liu, Xiaoqi Zheng, Jing‐Wen Lin, Yu Chen, Fengming Luo, Huajing Wan   +10 more
wiley   +1 more source

Molnupiravir. Arabic

, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 ARABIC"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

MOLNUPIRAVIR AS A PROMISING AGENT AGAINST COVID-19: A REVIEW

, 2022
Coronaviruses can cause illness in people all around the world. They typically cause respiratory infections ranging from the common cold to more serious diseases like middleeast respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS ...
Sajjad Husain Ansari, Nandre pratik, Asif Ansari
core   +1 more source

Fullerene Derivatives for Drug Delivery against COVID-19: A Molecular Dynamics Investigation of Dendro[60]fullerene as Nanocarrier of Molnupiravir

Nanomaterials, 2022
In this paper, a theoretical investigation is made regarding the possibility of using a water-soluble derivative of C60 as a drug delivery agent for treating Coronavirus disease 2019 (COVID-19).
Georgios I. Giannopoulos
doaj   +1 more source

Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild‐to‐Moderate COVID‐19 Cases in a Broadly Immune Population

Medical Journal of Australia, Volume 224, Issue 7, July 2026.
ABSTRACT Antivirals for mild‐to‐moderate coronavirus disease 2019 (COVID‐19) were adopted for use based on trials in unvaccinated adults during the pre‐Omicron period. In today's broadly immune populations, where the risk of hospitalisation and death has decreased substantially, there is a lack of high‐quality contemporary evidence to support routine ...
Hadar Mudrik‐Zohar, Tim Cutfield, Susan Morpeth, Thomas Hills, Eamon Duffy, Laura J. Edwards, Allen C. Cheng, Steven Y. C. Tong   +7 more
wiley   +1 more source

Molnupiravir. Hmong

, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 HMONG"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Infectious Diseases and Therapy, 2023
Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for outpatient treatment of mild-to-moderate COVID-19, significantly reducing the risk of ...
Julie M. Strizki, Jay A. Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G. Johnson, Jiejun Du, Patricia Carmelitano, Michelle L. Brown, Amanda Paschke, Carisa De Anda   +9 more
doaj   +1 more source

Revisiting Hydrazine Moiety as a Scaffold for the Synthesis of Potential Antiviral Pyrazole Ribonucleoside Analogues

ChemMedChem, Volume 21, Issue 11, 15 June 2026.
Three series of pyrazole ribonucleoside analogues were designed and synthesized. They were evaluated, along with some of their pronucleotides, for their antiviral activity against RNA viruses. Pyrazole ribonucleoside analogues were prepared via a linear approach starting with the reaction of D‐ribosylhydrazine with 1,3‐dicarbonyl or acrylonitrile ...
Anaïs Guillou, Nathalie Gros, Delphine Muriaux, Suzanne Peyrottes, Jean‐Jacques Vasseur, Michael Smietana, Christophe Mathé   +6 more
wiley   +1 more source